Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx

This study has been completed.
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: July 10, 2007
Last updated: January 7, 2013
Last verified: January 2013

RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with radiation therapy, with or without lapatinib, before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed or eliminate the need for surgery.

PURPOSE: This phase I/II trial is studying the side effects and best dose of combination chemotherapy given together with radiation therapy with or without lapatinib and to see how well it works in treating patients with locally advanced cancer of the larynx or hypopharynx.

Condition Intervention Phase
Head and Neck Cancer
Drug: carboplatin
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil
Drug: lapatinib ditosylate
Genetic: cytogenetic analysis
Genetic: fluorescence in situ hybridization
Genetic: in situ hybridization
Genetic: polymerase chain reaction
Genetic: reverse transcriptase-polymerase chain reaction
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: fludeoxyglucose F 18
Radiation: radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Maximum tolerated dose of lapatinib ditosylate (Phase I) [ Designated as safety issue: Yes ]
  • Dose-limiting toxicities of lapatinib ditosylate (Phase I) [ Designated as safety issue: Yes ]
  • Recommended dose of lapatinib ditosylate (Phase I) [ Designated as safety issue: No ]
  • Feasibility (Phase II) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity (Phase II) [ Designated as safety issue: Yes ]
  • Survival with functional larynx (i.e., alive without local progression/relapse, tracheotomy, feeding tube, gastrostomy, or laryngectomy) (Phase II) [ Designated as safety issue: No ]
  • Response rate (CR and PR) of neoadjuvant treatment (Phase II) [ Designated as safety issue: No ]
  • Overall response rate (Phase II) [ Designated as safety issue: No ]
  • Rate of local relapse (Phase II) [ Designated as safety issue: No ]
  • Distant metastasis (Phase II) [ Designated as safety issue: No ]
  • Overall survival (Phase II) [ Designated as safety issue: No ]
  • Predictive value of PET to spare neck dissection in N1-3 patients (Phase II) [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: May 2007
Study Completion Date: March 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed newly diagnosed squamous cell carcinoma of the larynx or hypopharynx

    • T3 or T4 disease of the larynx or T2, T3 or T4 disease of the hypopharynx
    • Nodal status must be N0, N1, N2a, N2b, N2c or N3
  • Resectable or unresectable disease (Phase I patients only)
  • Patient must have tumors amenable to surgery (Phase II patients only)
  • No distant metastasis


  • WHO performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin < 1.5 times the upper limit of the normal range
  • Alkaline phosphatase and transaminases < 2.5 times the upper limit of the normal range
  • Serum creatinine < 1.7 mg/dL
  • All patients (male and female) must use effective contraception methods if of reproductive potential (e.g., implants, injectables, combined oral contraceptives, IUDs, sexual abstinence, or vasectomized partner)
  • Females must not be pregnant or lactating
  • Patients must have normal cardiac function (LVEF assessed by MUGA or ECHO) and clinically satisfactory 12-lead ECG
  • No serious cardiac illness or medical condition within the past 6 months including, but not limited to, any of the following:

    • History of documented congestive heart failure
    • High-risk uncontrolled arrhythmias
    • Angina pectoris requiring antianginal medication
    • Clinically significant valvular heart disease
    • Evidence of transmural infarction on ECG
    • Poorly controlled hypertension (e.g., systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg)
  • Patients should be able to swallow oral agents
  • No current malignancies at other sites with the exception of cone biopsied carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma or other cancer from which the patient has been disease-free for at least five years
  • Absence of any unstable systemic diseases or active uncontrolled infections
  • Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule


  • No other prior therapy for head and neck cancer
  • More than 10 days since prior and no concurrent CYP3A4 inducers, including the following:

    • Antibiotics (e.g., all rifamycin class agents [rifampicin, rifabutin, or rifapentine])
    • Anticonvulsants (e.g., phenytoin, carbamezepine, or barbiturates [phenobarbital])
    • Oral glucocorticoids (e.g., cortisone [> 50 mg], hydrocortisone [> 40 mg], prednisone [> 10 mg], methylprednisolone [> 8 mg], or dexamethasone [> 1.5 mg])
    • Antiretrovirals (e.g., efavirenz or nevirapine)
    • Other (hypericum perforatum [St. John's Wort] or modafinil)
  • More than 10 days since prior and no concurrent CYP3A4 inhibitors, including the following:

    • Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)
    • Antifungals (e.g., itraconazole, ketoconazole, fluconazole [> 150 mg daily], or voriconazole)
    • Antiretrovirals and protease inhibitors (e.g., delavirdine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)
    • Calcium channel blockers (e.g., verapamil or diltiazem)
    • Antidepressants (e.g., nefazodone or fluvoxamine)
    • Gastrointestinal agents (e.g., cimetidine or aprepitant)
    • Other (e.g., grapefruit, grapefruit juice, or camiodarone)
    • Miscellaneous (e.g., antacids [Mylanta, Maalox, Tums, or Rennies], all herbal [bergamottin or glabridin] or dietary supplements)
  • Patients may not receive any other anticancer therapy or investigational agents while on study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00498953

Institut Jules Bordet
Brussels, Belgium, 1000
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Ahmad Awada, MD, PhD Institut Jules Bordet
  More Information

Additional Information:
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00498953     History of Changes
Other Study ID Numbers: EORTC-24051, 2006-002667-33, GSK-EORTC-24051
Study First Received: July 10, 2007
Last Updated: January 7, 2013
Health Authority: United States: Federal Government

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
stage II squamous cell carcinoma of the hypopharynx
stage III squamous cell carcinoma of the hypopharynx
stage IV squamous cell carcinoma of the hypopharynx
stage III squamous cell carcinoma of the larynx
stage IV squamous cell carcinoma of the larynx

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Fluorodeoxyglucose F18
Antineoplastic Agents
Diagnostic Uses of Chemicals
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses processed this record on September 03, 2015